Rheumatology International

, Volume 25, Issue 4, pp 296–300

Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: a pilot study

  • J. D. Ringe
  • A. Dorst
  • H. Faber
  • C. Kipshoven
  • L. C. Rovati
  • I. Setnikar
Original Article

DOI: 10.1007/s00296-004-0570-x

Cite this article as:
Ringe, J.D., Dorst, A., Faber, H. et al. Rheumatol Int (2005) 25: 296. doi:10.1007/s00296-004-0570-x

Abstract

In a three-year pilot study on 52 women with severe postmenopausal osteoporosis, treatment with etidronate followed by calcium and vitamin D (ECaD) was compared to etidronate followed by monofluorophosphate, calcium and vitamin D (EFCaD). BMD in lumbar spine, total hip and femoral neck increased significantly more with EFCaD than with ECaD. Pain-mobility score decreased significantly more with EFCaD than with ECaD (p=0.006). New vertebral fractures occurred in three patients under EFCaD (12%) and in nine under ECaD (35%), (p=0.048). Three patients under EFCaD (12%) and 15 under ECaD (58%) did not respond to therapy (p of difference=0.001). Mild or moderate adverse reactions were reported by 25 patients, with no significant difference between the two groups. The pilot study suggests that etidronate, sequentially followed by monofluorophosphate, could be a safe, effective and relatively inexpensive therapy in severe postmenopausal osteoporosis.

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • J. D. Ringe
    • 1
  • A. Dorst
    • 1
  • H. Faber
    • 1
  • C. Kipshoven
    • 2
  • L. C. Rovati
    • 3
  • I. Setnikar
    • 3
  1. 1.Klinikum Leverkusen (University of Cologne)LeverkusenGermany
  2. 2.Opfermann Arzneimittel GmbHWiehlGermany
  3. 3.Rotta Research LaloratoriumMonzaItaly